ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 73 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $31,510 | -82.0% | 13,700 | -78.7% | 0.00% | – |
Q2 2022 | $175,000 | -75.1% | 64,400 | -72.7% | 0.00% | -100.0% |
Q1 2022 | $704,000 | -47.4% | 236,200 | -31.4% | 0.00% | -33.3% |
Q4 2021 | $1,339,000 | +169.4% | 344,300 | +197.3% | 0.00% | +200.0% |
Q3 2021 | $497,000 | -27.0% | 115,800 | -48.4% | 0.00% | -50.0% |
Q2 2021 | $681,000 | -51.5% | 224,600 | -46.7% | 0.00% | -50.0% |
Q1 2021 | $1,403,000 | +1770.7% | 421,200 | +1647.7% | 0.00% | – |
Q3 2020 | $75,000 | -75.2% | 24,100 | -85.5% | 0.00% | -100.0% |
Q2 2020 | $303,000 | +124.4% | 166,700 | +24.4% | 0.00% | 0.0% |
Q1 2020 | $135,000 | -40.0% | 134,000 | +65.4% | 0.00% | 0.0% |
Q4 2019 | $225,000 | +86.0% | 81,000 | +2.1% | 0.00% | – |
Q3 2019 | $121,000 | -32.8% | 79,300 | -8.2% | 0.00% | – |
Q2 2019 | $180,000 | +41.7% | 86,400 | +142.7% | 0.00% | – |
Q1 2019 | $127,000 | +101.6% | 35,600 | +117.1% | 0.00% | – |
Q4 2018 | $63,000 | -52.6% | 16,400 | +16.3% | 0.00% | – |
Q3 2018 | $133,000 | – | 14,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 3,705,128 | $10,300,000 | 4.44% |
RTW INVESTMENTS, LP | 5,666,754 | $15,754,000 | 0.59% |
COWEN AND COMPANY, LLC | 926,200 | $2,575,000 | 0.22% |
Hudson Bay Capital Management LP | 850,000 | $2,363,000 | 0.05% |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,774,915 | $4,934,000 | 0.03% |
Point72 Asset Management, L.P. | 1,897,284 | $5,274,000 | 0.03% |
683 Capital Management, LLC | 77,368 | $215,000 | 0.02% |
Secure Asset Management, LLC | 10,000 | $28,000 | 0.02% |
Qube Research & Technologies Ltd | 166,138 | $462,000 | 0.01% |
Verition Fund Management LLC | 174,455 | $485,000 | 0.01% |